Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aridis Pharmaceuticals Inc.

0.0001
+0.0000
Volume:- -
Turnover:- -
Market Cap:4.46K
PE:0.00
High:0.0001
Open:0.0001
Low:0.0001
Close:0.0001
Loading ...

Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
20 Mar

Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Dow Jones
·
18 Mar

Healios K.K Submits Approval Application for ARDS Treatment in Japan

MT Newswires Live
·
13 Mar

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire
·
07 Mar

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire
·
28 Feb

Bonus Biogroup Gains FDA Approval for Crucial Phase III ARDS Drug Trial

TIPRANKS
·
18 Feb

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
13 Feb

EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo…

Zacks Small Cap Research
·
22 Jan

Healios Launches Medical Materials Division to Boost Culture Supernatant Supply

MT Newswires Live
·
20 Jan

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Zacks
·
16 Jan

Healios, Nobelpharma End Collaboration Talks for MultiStem ARDS Agreement

MT Newswires Live
·
16 Jan

Healios Reaches Agreement with PMDA on MultiStem ARDS Approval in Japan

MT Newswires Live
·
16 Jan

InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS

TIPRANKS
·
16 Jan

InflaRx announces EC grants marketing authorization to Gohibic for ARDS

TIPRANKS
·
16 Jan

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire
·
16 Jan

Healios Ends Collaboration Talks with Nobelpharma on ARDS Therapy

TIPRANKS
·
15 Jan